Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven ovarian epithelial cancer
• * Progressive disease during or after completion of at least one platinum based chemotherapy regimen
• Bidimensionally measurable disease
• * At least 2 cm by x-ray, CT scan, or ultrasound
• No active, symptomatic brain metastases (e.g., cerebral edema and/or progressive tumor growth)
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• WHO 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Hemoglobin at least 10 g/dL
• WBC at least 4,000/mm3
• Platelet count at least 100,000/mm3
• Hepatic:
• Bilirubin no greater than 1.7 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
• Renal:
• Creatinine no greater than 1.4 mg/dL
• Other:
• No active, uncontrolled infection
• No nonmalignant systemic disease which would increase risk to patient
• No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy and recovered
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered
• No more than 2 prior multidrug chemotherapy regimens
• No more than 1 prior single agent chemotherapy regimen
• Endocrine therapy:
• At least 4 weeks since prior endocrine therapy and recovered
• No concurrent steroids
• Concurrent hormone replacement therapy allowed
• Radiotherapy:
• At least 4 weeks since prior radiotherapy (excluding palliative therapy) and recovered
• No concurrent radiotherapy
• Surgery:
• At least 4 weeks since prior major thoracic or abdominal surgery
• Other:
• No other concurrent anticancer therapy or investigational drugs